RU2004112762A - Модуль инактивации лейкоцитов (lim) - Google Patents
Модуль инактивации лейкоцитов (lim) Download PDFInfo
- Publication number
- RU2004112762A RU2004112762A RU2004112762/15A RU2004112762A RU2004112762A RU 2004112762 A RU2004112762 A RU 2004112762A RU 2004112762/15 A RU2004112762/15 A RU 2004112762/15A RU 2004112762 A RU2004112762 A RU 2004112762A RU 2004112762 A RU2004112762 A RU 2004112762A
- Authority
- RU
- Russia
- Prior art keywords
- ligand
- module
- leukocytes
- activity
- carrier
- Prior art date
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract 13
- 230000002779 inactivation Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 claims abstract 13
- 230000000694 effects Effects 0.000 claims abstract 5
- 102000004127 Cytokines Human genes 0.000 claims abstract 2
- 108090000695 Cytokines Proteins 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims abstract 2
- 108090000790 Enzymes Proteins 0.000 claims abstract 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims abstract 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims 7
- 102000005962 receptors Human genes 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Модуль для уменьшения активности лейкоцитов, который содержит носитель и лиганд, который связан с этим носителем и является пригодным для взаимодействия с рецептором лейкоцитов.
2. Модуль по п.1, в котором указанный лиганд является антителом против рецептора лейкоцитов.
3. Модуль по п.1, в котором этот лиганд является белком, который пригоден для специфического взаимодействия с указанным рецептором.
4. Модуль по п.3, в котором указанный лиганд является антителом против рецептора лейкоцитов.
5. Модуль по п.1 или 3, в котором этот лиганд связан с медиатором связывания, связанным с носителем.
6. Модуль по п.5, в котором указанный лиганд является антителом против рецептора лейкоцитов.
7. Модуль по п.5, в котором медиатором связывания является клетка.
8. Модуль по п.7, в котором медиатором связывания является клетка, а лигандом является белок FasL.
9. Модуль по п.7, в котором указанный лиганд является антителом против рецептора лейкоцитов.
10. Модуль по любому из пп.2, 4, 6, или 9, в котором указанный лиганд является антителом против белка Fas лейкоцитов.
11. Способ уменьшения активности лейкоцитов путем контактирования с лигандами в модуле по любому из пп.1-10.
12. Способ по п.11, в котором лейкоциты после контактирования с указанными лигандами секретируют цитокины и/или ферменты и/или радикалы кислорода в меньшем количестве, чем перед контактированием.
13. Способ по п.11 или 12, в котором взаимодействие лиганда, связанного с клеткой, с рецептором лейкоцитов уменьшает активность лейкоцитов в переводе на аффинность связывание с данной клеткой.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10147638A DE10147638B4 (de) | 2001-09-27 | 2001-09-27 | Leukozyten-Inaktivierungs-Modul (LIM) |
| DE10147638.8 | 2001-09-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004112762A true RU2004112762A (ru) | 2005-04-20 |
| RU2327490C2 RU2327490C2 (ru) | 2008-06-27 |
Family
ID=7700470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004112762/15A RU2327490C2 (ru) | 2001-09-27 | 2002-09-16 | Модуль инактивации лейкоцитов (lim) |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20040241171A1 (ru) |
| EP (1) | EP1430085B1 (ru) |
| JP (1) | JP5503826B2 (ru) |
| CN (1) | CN100346822C (ru) |
| AT (1) | ATE438661T1 (ru) |
| BR (1) | BR0212816A (ru) |
| CA (1) | CA2461900A1 (ru) |
| DE (4) | DE20121877U1 (ru) |
| HU (1) | HUP0401803A2 (ru) |
| MX (1) | MXPA04002736A (ru) |
| NO (1) | NO20041682L (ru) |
| PL (1) | PL368596A1 (ru) |
| RU (1) | RU2327490C2 (ru) |
| WO (1) | WO2003031473A1 (ru) |
| ZA (1) | ZA200402205B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20121877U1 (de) | 2001-09-27 | 2003-09-18 | LeukoCare GmbH, 85646 Neufarn | Leukozyten-Inaktivierungs-Modul (LIM) |
| US20100306144A1 (en) * | 2009-06-02 | 2010-12-02 | Scholz Martin B | System and method for classifying information |
| JP6773217B2 (ja) * | 2017-04-28 | 2020-10-21 | ヤマハ株式会社 | 受信装置及び信号伝送システム |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443955A (en) * | 1989-01-27 | 1995-08-22 | Australian Membrane And Biotechnology Research Institute | Receptor membranes and ionophore gating |
| EP0478914B1 (en) * | 1990-07-27 | 1996-05-22 | Pall Corporation | Leucocyte depleting filter device and method of use |
| US5639376A (en) * | 1994-01-10 | 1997-06-17 | Hemasure, Inc. | Process for simultaneously removing leukocytes and methylene blue from plasma |
| WO1995018665A1 (en) * | 1994-01-10 | 1995-07-13 | Hemasure, Inc. | Device and process for removing leukocytes and viral inactivating agents from blood |
| JPH08173528A (ja) * | 1994-12-26 | 1996-07-09 | Terumo Corp | 血液処理システム |
| WO1997012632A1 (en) * | 1995-10-05 | 1997-04-10 | Tkb Associates Limited Partnership | Methods for treatment of diseases associated with a deficiency of fas ligand activity |
| WO1997038707A1 (en) * | 1996-04-17 | 1997-10-23 | Cytotherapeutics, Inc. | Method and device for delivery of apoptosis-inducing molecules |
| JPH1076004A (ja) * | 1996-09-05 | 1998-03-24 | Kanegafuchi Chem Ind Co Ltd | 体液処理用吸着材及び体液処理用吸着器 |
| WO1998046242A1 (en) * | 1997-04-11 | 1998-10-22 | Stanford University | Treatment of cancer by the administration of fas ligand expressing non-tumorigenic cells |
| US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| DK1126859T3 (da) * | 1999-03-17 | 2006-08-28 | Jimro Co Ltd | Blodleukocyt-aferese til behandling af HIV |
| JP2001103977A (ja) * | 1999-10-12 | 2001-04-17 | National Institute Of Animal Health | ブタＦａｓリガンドの構造遺伝子 |
| US6797514B2 (en) * | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| DE20121877U1 (de) | 2001-09-27 | 2003-09-18 | LeukoCare GmbH, 85646 Neufarn | Leukozyten-Inaktivierungs-Modul (LIM) |
-
2001
- 2001-09-27 DE DE20121877U patent/DE20121877U1/de not_active Expired - Lifetime
- 2001-09-27 DE DE10147638A patent/DE10147638B4/de not_active Expired - Fee Related
-
2002
- 2002-09-16 MX MXPA04002736A patent/MXPA04002736A/es active IP Right Grant
- 2002-09-16 WO PCT/DE2002/003466 patent/WO2003031473A1/de active Application Filing
- 2002-09-16 DE DE10294578T patent/DE10294578D2/de not_active Expired - Fee Related
- 2002-09-16 BR BR0212816-0A patent/BR0212816A/pt not_active IP Right Cessation
- 2002-09-16 CN CNB028188330A patent/CN100346822C/zh not_active Expired - Fee Related
- 2002-09-16 HU HU0401803A patent/HUP0401803A2/hu unknown
- 2002-09-16 JP JP2003534455A patent/JP5503826B2/ja not_active Expired - Fee Related
- 2002-09-16 CA CA002461900A patent/CA2461900A1/en not_active Abandoned
- 2002-09-16 DE DE50213747T patent/DE50213747D1/de not_active Expired - Lifetime
- 2002-09-16 RU RU2004112762/15A patent/RU2327490C2/ru not_active IP Right Cessation
- 2002-09-16 US US10/489,831 patent/US20040241171A1/en not_active Abandoned
- 2002-09-16 AT AT02782679T patent/ATE438661T1/de not_active IP Right Cessation
- 2002-09-16 EP EP02782679A patent/EP1430085B1/de not_active Expired - Lifetime
- 2002-09-16 PL PL02368596A patent/PL368596A1/xx not_active Application Discontinuation
-
2004
- 2004-03-19 ZA ZA200402205A patent/ZA200402205B/en unknown
- 2004-04-26 NO NO20041682A patent/NO20041682L/no not_active Application Discontinuation
-
2008
- 2008-05-02 US US12/114,349 patent/US7850969B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7850969B2 (en) | 2010-12-14 |
| HUP0401803A2 (hu) | 2004-11-29 |
| US20080292643A1 (en) | 2008-11-27 |
| DE20121877U1 (de) | 2003-09-18 |
| CN100346822C (zh) | 2007-11-07 |
| JP5503826B2 (ja) | 2014-05-28 |
| MXPA04002736A (es) | 2005-09-08 |
| PL368596A1 (en) | 2005-04-04 |
| EP1430085A1 (de) | 2004-06-23 |
| DE50213747D1 (de) | 2009-09-17 |
| NO20041682L (no) | 2004-04-26 |
| BR0212816A (pt) | 2004-10-05 |
| RU2327490C2 (ru) | 2008-06-27 |
| CA2461900A1 (en) | 2003-04-17 |
| CN1558915A (zh) | 2004-12-29 |
| EP1430085B1 (de) | 2009-08-05 |
| DE10294578D2 (de) | 2004-08-26 |
| ATE438661T1 (de) | 2009-08-15 |
| US20040241171A1 (en) | 2004-12-02 |
| WO2003031473A1 (de) | 2003-04-17 |
| JP2005507908A (ja) | 2005-03-24 |
| DE10147638B4 (de) | 2004-05-27 |
| ZA200402205B (en) | 2004-08-16 |
| DE10147638A1 (de) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005004120D1 (de) | System und verfahren zur übernahme von partner-betriebsmitteln in verbindung mit coredump | |
| DE60209813D1 (de) | Hydrogelschicht enthaltender, absorbierender wundverband | |
| ATE180261T1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
| ATE234092T1 (de) | 2-alkylpyrrolidine | |
| DE69433301D1 (de) | Methoden zur erhöhung der biologischen aktivität von chemokinen | |
| AR012010A1 (es) | Metodo para el procesamiento de una solucion acuosa de proteina c activada | |
| DE69434612D1 (de) | Monoklonale Antikörper gegen recombinantes Stratum Corneum chymotryptisches Enzym (SCCE) | |
| RU2004112762A (ru) | Модуль инактивации лейкоцитов (lim) | |
| ATE238061T1 (de) | Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten | |
| AU5301196A (en) | Method for stimulating an immune response | |
| DE69535590D1 (de) | Für den bradykinin-b1-rezeptor kodierende dna | |
| WO1999061468A3 (en) | The induction of antibiotic peptides by lait (scd14) protein | |
| RU2004106775A (ru) | Антитело против интерферон-альфа/бета-связывающего белка i (ifnab-bpi) | |
| DE69013730D1 (de) | Für ganze Zellen geeigneter Satz und Verfahren zu enzymatischen Bestimmungen. | |
| ATE274920T1 (de) | Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen | |
| ATE449161T1 (de) | Leukozytenstimulations-matrix | |
| DE69938827D1 (de) | Verwendung von inhibitoren von asparaginyl-endopeptidase aus säugetieren zur modulierung des immunsystemen | |
| AU2003232845A1 (en) | Method for the purification of microbial protease | |
| DE69502095D1 (de) | Festphasenimmunoassay zum nachweis von inhibitoren von einem proteolytischen enzym | |
| ATE134218T1 (de) | Methode zur reinigung rekombinanter t-pa von den ihren entsprechenden wirtszellproteinen | |
| ATE274067T1 (de) | Verwendung von socs-2 oder cis zum 'screenen' von substanzen, die einen wachstumshormoneffekt verstärken | |
| AU2002357820A1 (en) | Diagnostic methods for protein profiling | |
| FR2837836B1 (fr) | UTILISATION DE LA PROTEINE Maba (FABG1) DE MYCOBACTERIUM TUBERCULOSIS POUR LA CONCEPTION ET LE CRIBLAGE D'ANTIBIOTIQUES | |
| SE9901807D0 (sv) | Method for the removal of an enzyme from a liquid | |
| AU3733199A (en) | Antibodies and utilization thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180917 |